PT  - JOURNAL ARTICLE
AU  - Wei, Dongmei
AU  - Melgarejo, Jesus D.
AU  - Van Aelst, Lucas
AU  - Vanassche, Thomas
AU  - Verhamme, Peter
AU  - Janssens, Stefan
AU  - Peter, Karlheinz
AU  - Zhang, Zhen-Yu
TI  - Prediction of Coronary Artery Disease Using Urinary Proteomics
AID  - 10.1101/2023.02.09.23285646
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.09.23285646
4099  - http://medrxiv.org/content/early/2023/02/10/2023.02.09.23285646.short
4100  - http://medrxiv.org/content/early/2023/02/10/2023.02.09.23285646.full
AB  - Aims Coronary artery disease (CAD) is multifactorial, caused by complex pathophysiology, and contributes to a high burden of mortality worldwide. Urinary proteomic analyses may help to identify predictive biomarkers and provide insights into the pathogenesis of CAD.Methods Urinary proteome was analyzed in 965 participants using capillary electrophoresis coupled with mass spectrometry. A proteomic classifier was developed in a discovery cohort with 36 individuals with CAD and 36 matched controls using the support vector machine. The classifier was tested in a validation cohort with 115 individuals who progressed to CAD and 778 controls and compared with two previously developed CAD-associated classifiers, CAD238 and ACSP75. The Framingham risk score was available in 737 participants. Bioinformatics analysis was performed based on the CAD-associated peptides.Results The novel proteomic classifier was comprised of 160 urinary peptides, mainly related to collagen turnover, lipid metabolism, and inflammation. In the validation cohort, the classifier provided an AUC of 0.82 (95% CI: 0.78-0.87) for the CAD prediction in 8 years, superior to CAD238 (AUC: 0.71, 95% CI: 0.66-0.77) and ACSP75 (AUC: 0.53, 95% CI: 0.47-0.60). On top of CAD238 and ACSP75, the addition of the novel classifier improved the AUC to 0.84 (95% CI: 0.80-0.89). In a multivariable Cox model, a 1-SD increment in the novel classifier was associated with CAD (HR: 1.54, 95% CI: 1.26-1.89, P<0.0001) higher risk of CAD. The new classifier further improved the risk reclassification of CAD on top of the Framingham risk score (net reclassification index: 0.61, 95% CI: 0.25-0.95, P=0.001).Conclusions A novel urinary proteomic classifier related to collagen metabolism, lipids, and inflammation showed potential for the risk prediction of CAD. Urinary proteome provides an alternative approach to personalized prevention.Lay summaryA biomarker that can predict coronary artery disease (CAD) is in urgently need.We developed and validated a urinary proteomic classifier for the prediction of CAD.The proteomic classifier involved in atherosclerosis improved the risk reclassification on top of the clinical risk score.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe European Research Area Net for Cardiovascular Diseases (JTC2017-046-PROACT), and KU Leuven (STG-18-00379) currently support the Studies Coordinating Centre in Leuven.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was a retrospective longitudinal study, comprised of a discovery cohort and a validation cohort. The discovery cohort consisted of cases and matched controls from a population-based study, the Flemish Study on Environment, Genes, and Health Outcomes (FLEMENGHO). The validation cohort was comprised of 893 individuals (115 with and 778 without CAD) from the FLEMENGHO study (35 with and 702 without CAD) or extracted from the Human Urinary Proteome Database (80 with and 76 without CAD), consisting of more than 85000 samples from various clinical and research centers. All the latter datasets were fully anonymized and previously published, with respective references provided in the manuscript. Demographic and clinical characteristics from extracted datasets included sex, age, hypertension, diabetes, office blood pressure, and estimated glomerular filtration rate (eGFR). The second use of FLEMENGHO study data (B32220083510) was approved by the University of Leuven Ethics Committee and participants provided written informed consent. Datasets extracted from the Human Urinary Proteome Database were previously published and relevant studies were conducted in compliance with the Helsinki declaration for research in humans and received an approval from the responsible review boards.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article cannot be shared publicly due to the privacy of the participants. The data can only be reasonably requested to the corresponding author